Navigation Links
Zargis Cleared as Apple iPhone Developer; Medical Applications for Smartphones Planned
Date:10/21/2009

STAMFORD, Conn., Oct. 21 /PRNewswire/ -- Zargis Medical Corp., a subsidiary of Speedus Corp. (Nasdaq: SPDE) and a spin-off from Siemens Corporate Research (NYSE: SI), today announced that is has been cleared as an Apple(®) iPhone(®) developer and has begun development of medical diagnostic support software and related peripherals for the iPhone and other leading smartphones.

Zargis has identified the handheld environment as a logical delivery platform for its telemedicine and diagnostic software initiatives, and with its team of experienced developer's plans to leverage the smartphone platform as a mobile hub between medical device peripherals and computer-aided diagnostic support located either locally or remotely.

A recent report released by Manhattan Research stated that 64% of doctors, more than double the number eight years ago, own smartphones, and that this figure will increase to 81% penetration in 2012. However, despite the rapid adoption of the iPhone and other smartphones by physicians, currently available healthcare applications for these devices are generally limited to medical reference libraries, educational tools and applications designed to manage patient medical records.

"The future of healthcare delivery is about connectivity and mobility. Zargis' expertise in computer-aided auscultation and our advanced medical software platform positions us perfectly to create diagnostic software and peripherals that are a natural fit for smartphones. We intend to improve healthcare efficiency by helping clinicians bring medical technology to the patient, rather than the other way around," stated Zargis CEO John Kallassy.

About Zargis Medical Corp.

Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE: SI), and Speedus Corp. co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds.

For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or phodge@zargis.com or visit the following Web sites: www.zargis.com and www.speedus.com.

Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.

iPhone and Apple are registered trademarks of Apple Inc.

SOURCE Zargis Medical Corp.


'/>"/>
SOURCE Zargis Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Zargis Receives FDA Clearance for Signal X6 Telemedicine Device; OK Allows Delivery to US Army
2. Zargis Cardioscan(TM) Unveiled Through Global Marketing and Distribution Alliance With 3M Company
3. 3M and Zargis Announce Global Marketing Alliance
4. NBTY Acquisition of Julian Graves Unconditionally Cleared
5. Inverness Medical Innovations Launches New FDA Cleared C. DIFF QUIK CHEK COMPLETE(TM) Rapid Test
6. HemAway(R) Launches FDA-Cleared Painless Hemorrhoid Treatment Device
7. Mount Sinai first in US to implant FDA-cleared ring for mitral valve repair
8. Amedica Receives CE Mark for the Worlds First FDA-Cleared Valeo(TM) Ceramic Spinal Implant System
9. Clearwater's Canadian at-Home Dizziness Treatment Device Cleared by FDA
10. OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA
11. Rejuvasun(TM) With Omnilux(TM): Industry First to Feature FDA-Cleared, Clinically Proven Light Therapy Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Program will serve more than ... the U.S. Soccer Foundation announced today that they have awarded nine grants to ... the Foundation’s soccer mentoring program, teaches kids the fundamentals of soccer while striving ...
(Date:2/17/2017)... ... 17, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... – 22 in San Francisco. As part of the Tri-Conference expo, which is ... solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... planning assistance to families and business owners in the greater Fort Lauderdale metropolitan ... organization. , For more than 30 years, LifeNet 4 Families has provided ...
(Date:2/16/2017)... Birmingham, AL (PRWEB) , ... February 17, 2017 ... ... asset protection assistance and financial planning services to families and entrepreneurs in the ... Bonnie, a local adoptive mother who needs assistance with her medically challenged son, ...
(Date:2/16/2017)... Angeles, CA (PRWEB) , ... February 16, 2017 , ... ... be confusing to the average patient. Parsa Mohebi, founder of Parsa Mohebi Hair Restoration, ... educate the public about the field of hair restoration, he recently expanded the information ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... --  Risperdal lawsuits involving gynecomastia (male breast growth) ... the atypical antipsychotic medication continue to move forward in ... Pleas, where the state,s Risperdal docket has been centralized ... posted on the Court,s website , the litigation ... 2017 at 11:00 a.m. (In Re: Risperdal Litigation, Case ...
(Date:2/17/2017)... Feb. 17, 2017  Featuring new ... at the  2017 HIMSS Conference & Exhibition (HIMSS17 ),  ... a global leader in health ... of population health management, acute healthcare ... integrated in a highly secure, cloud-based ...
(Date:2/17/2017)... YORK , Feb. 17, 2017  Noble Capital ... on ESSA Pharma Inc. (Nasdaq: EPIX ). ... Research, Kumar Raja , PhD. ESSA ... for castration resistant prostate cancer (CRPC). Its lead compound ... blocks the amino-terminal domain of the androgen receptor, thereby ...
Breaking Medicine Technology: